Incyte

INCY

Market cap $23B

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio.

Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.

As of June 29, SA Quant's portfolio of Top 10 Stocks for 2026 has significantly outperformed the market, up nearly 70% vs. the S&P 500's 8.3%. Four of the 10 stocks have delivered triple-digit returns, with standout performances from Micron and AMD, up 267% and 156%, respectively, since they were selected on January 6, 2026. Eight of the ten stocks carry Strong Buy Quant Ratings, and the entire basket continues to exhibit solid growth and earnings revisions.

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a $159.5/share price target. Recent catalysts include a positive CHMP opinion for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding INCY's product portfolio and reducing Jakafi concentration risk. Q1 2026 results showed robust diversification: revenues up 21% YoY, adjusted EPS up 56% YoY, and ex-Jakafi sales up 63% YoY.

MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis.

Futures are trading mixed as we prepare to finish the last full week of the second quarter.